Benzinga | Sep 30, 2021 05:05AM EDT

JP Morgan Upgrades Amicus Therapeutics to Overweight, Announces $16 Price Target

JP Morgan analyst Anupam Rama upgrades Amicus Therapeutics (NASDAQ:FOLD) from Neutral to Overweight and announces $16 price target.